

## 1 **Increased plasma heparanase activity in COVID-19 patients**

2

3 Baranca Buijsers<sup>1\*</sup>, Cansu Yanginlar<sup>1\*</sup>, Aline de Nooijer<sup>2†</sup>, Inge Grondman<sup>2†</sup>, Marissa L.  
4 Maciej-Hulme<sup>1</sup>, Inge Jonkman<sup>1</sup>, Nico A.F. Janssen<sup>2</sup>, Nils Rother<sup>1</sup>, Mark de Graaf<sup>1</sup>, Peter  
5 Pickkers<sup>2,3</sup>, Matthijs Kox<sup>2,3</sup>, Leo A.B. Joosten<sup>2</sup>, Tom Nijenhuis<sup>1</sup>, Mihai G. Netea<sup>2,4</sup>, Luuk  
6 Hilbrands<sup>1</sup>, Frank L. van de Veerdonk<sup>2</sup>, Raphaël Duivenvoorden<sup>1,5</sup>, Quirijn de Mast<sup>2</sup>, Johan  
7 van der Vlag<sup>1#</sup>

8

9 <sup>1</sup>Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud  
10 university medical center, Nijmegen, The Netherlands.

11 <sup>2</sup>Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud  
12 University Medical Center, Nijmegen, The Netherlands

13 <sup>3</sup>Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The  
14 Netherlands

15 <sup>4</sup>Department of Immunology and Metabolism, Life & Medical Sciences Institute, University of  
16 Bonn, Bonn, Germany

17 <sup>5</sup>Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai,  
18 New York, NY, USA.

19

20 \*co-first †co-second

21

22 #Corresponding author:

23 Prof. Dr. Johan van der Vlag

24 Department of Nephrology (480)

25 Radboud Institute for Molecular Life Sciences

26 Radboud university medical center

27 Geert Grooteplein 10

28 6525 GA Nijmegen

29 The Netherlands.

30 Email: [Johan.vanderVlag@radboudumc.nl](mailto:Johan.vanderVlag@radboudumc.nl)

31 ORCID: 0000-0001-7843-5918

32

33 **Article type:**

34 Short Report

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 **Abstract**

36 Reports suggest a role of endothelial dysfunction and loss of endothelial barrier function in  
37 COVID-19. It is well established that the endothelial glyocalyx-degrading enzyme  
38 heparanase contributes to vascular leakage and inflammation. Low molecular weight  
39 heparins (LMWH) serve as an inhibitor of heparanase. We hypothesize that heparanase  
40 contributes to the pathogenesis of COVID-19, and that heparanase may be inhibited by  
41 LMWH. Heparanase activity and heparan sulfate levels were measured in plasma of healthy  
42 controls (n=10) and COVID-19 patients (n=48).  
43 Plasma heparanase activity and heparan sulfate levels were significantly elevated in COVID-  
44 19 patients. Heparanase activity associated with disease severity including the need for  
45 intensive care and mechanical ventilation, lactate dehydrogenase levels and creatinine  
46 levels. Use of prophylactic LMWH in non-ICU patients was associated with a reduced  
47 heparanase activity. Since there is no other clinically applied heparanase inhibitor currently  
48 available, therapeutic treatment of COVID-19 patients with low molecular weight heparins  
49 should be explored.

## 50 **Introduction**

51 The coronavirus disease-2019 (COVID-19) pandemic is caused by the severe acute  
52 respiratory syndrome coronavirus 2 (SARS-CoV-2).<sup>1</sup> Severe COVID-19 usually manifests as  
53 pneumonitis or acute respiratory distress syndrome (ARDS).<sup>2,3</sup> Studies showed that upon  
54 hospital admission 59% of COVID-19 patients had proteinuria<sup>4</sup>, and 22% of the non-  
55 ventilated patients and 90% of the ventilated patients developed acute kidney injury (AKI).<sup>5,6</sup>  
56 Endothelial barrier function is crucial in the regulation of fluid and protein extravasation,  
57 particularly in the lungs<sup>7,8</sup> and in the kidneys.<sup>9,10</sup> An important role for endothelial cell  
58 dysfunction in the pathogenesis of the complications of COVID-19 has been proposed by  
59 several studies.<sup>11,12</sup> As pulmonary edema occurs when fluid leaks into alveoli, dysfunction of  
60 the endothelium is likely to contribute to pulmonary edema in COVID-19. Furthermore, it has  
61 been well established that proteinuria occurs when the endothelial barrier function in the  
62 glomerulus is compromised.<sup>9,10,13</sup>  
63 Endothelial cells are covered with a thick layer of negatively charged glycosaminoglycans  
64 (GAGs), termed the glycocalyx. Heparan sulfate (HS) is the predominant sulfated GAG in  
65 the glycocalyx. HS contributes to the endothelial charge-dependent barrier function due to its  
66 negative charge.<sup>14</sup> Degradation of HS by heparanase (HPSE), the only known mammalian  
67 HS-degrading enzyme, disrupts the endothelial glycocalyx and subsequent loss of  
68 endothelial barrier function, as observed in ARDS and proteinuric kidney diseases.<sup>7,15-17</sup> In  
69 addition to compromising barrier function, HPSE generates a pro-inflammatory glycocalyx  
70 that promotes the binding of chemokines, cytokines and leukocytes to the endothelial cell  
71 surface. Inhibition of HPSE and/or HPSE deficiency is beneficial in experimental lung and  
72 kidney diseases.<sup>7,15-18</sup> Notably, heparins and low molecular weight heparin (LMWH) that  
73 have been suggested to be beneficial for COVID-19 patients<sup>19</sup>, are potent inhibitors of  
74 HPSE activity.<sup>20,21</sup>  
75 Taken together, we hypothesize that increased HPSE activity is one of the driving forces in  
76 severe COVID-19 manifestation and that HPSE may be inhibited by the use of LMWH in  
77 COVID-19.


78 **Results**

79 ***Plasma HPSE activity is elevated in COVID-19 patients***

80 Demographics and baseline characteristics of COVID-19 patients are listed in Table 1.

81 Several (experimental) disease models have shown that increased HPSE activity can lead to  
82 endothelial barrier dysfunction, which may be involved in the development of ARDS and  
83 proteinuria/AKI.<sup>7,22,23</sup> Measurement of plasma HPSE activity levels in COVID-19 patients and  
84 healthy controls revealed that HPSE activity was significantly elevated in COVID-19 patients  
85 compared to healthy controls (Figure 1A). In line with the increased HPSE activity, HS  
86 plasma levels were also significantly elevated in COVID-19 patients compared to healthy  
87 controls (Figure 1B). Overall, these results suggest that SARS-CoV-2 infection causes an  
88 increase in the activity of HPSE in plasma and an increase in circulating HS.

89



90

91 **Figure 1. COVID-19 patients display increased HPSE activity and elevated levels of heparan sulfate in**  
92 **plasma. A.** HPSE activity was increased in plasma of COVID-19 patients compared to healthy controls. HPSE  
93 activity was measured using an in-house developed ELISA with a specific anti-HS antibody. **B.** HS levels were  
94 increased in plasma of COVID-19 patients compared to healthy controls. HS levels were measured by an in-  
95 house developed competition ELISA using a specific anti-HS antibody. Data were presented as mean±SEM and  
96 tested for normal distribution with D'Agostino & Pearson omnibus normality test and statistical differences were  
97 calculated using Mann Whitney test (n=10 healthy; n=48 COVID-19, \*\*\* p<0.001, \*\*\*\* p <0.0001). HPSE,  
98 heparanase; HS, heparan sulfate; Healthy, healthy controls; COVID-19, coronavirus disease-19 patients; AU,  
99 arbitrary units.

100

101 **Table 1. Demographics and baseline characteristic of COVID-19 patients\***

Characteristics	All patients	ICU	Non-ICU			p <sub>2</sub>	
	n=48	n=14	LMWH- n=17	LMWH+ n=17	Total n=34	p <sub>1</sub>	
<b>Sex, male, n (%)</b>	37 (77)	11 (78.5)	13 (76.5)	13 (76.5)	26 (76.5)	1.0000	1.0000
<b>Age, median (IQR), yr</b>	67.5 (57.3-74.75)	62.5 (53.0-69.5)	69 (62.5-76.5)	69 (53.5-77.0)	69 (58.8-77.0)	0.6792	0.2428
<b>Hospital stay, median (IQR), days</b>	9 (5-16)	26 (16-...)&	5 (5-8)	9 (6-12)	7 (5-9)	0.0443	0.0001
<b>Day of sampling (IQR)</b>	2 (1-3)	3 (1-6)	1 (1-2)	2 (2-4)	2 (1-3)	0.0089	0.1378
<b>Coexisting disorder, n (%)</b>							
Heart disease	8 (16.7)	3 (21.4)	3 (17.6)	2 (11.8)	5 (14.7)	1.0000	0.6757
Lung disease	16 (33.3)	4 (28.6)	2 (11.8)	10 (58.8)	12 (35.3)	0.0104	0.7460
Diabetes	6 (12.5)	2 (14.3)	3 (17.6)	1 (5.9)	4 (11.8)	0.6012	1.0000
Hypertension	18 (37.5)	8 (72.7)	5 (29.4)	5 (29.4)	10 (29.4)	1.0000	0.1032
Malignancy	9 (18.8)	1 (7.1)	4 (23.5)	4 (23.5)	8 (23.5)	1.0000	0.2501
Immunocompromised	7 (14.6)	0 (0)	2 (11.8)	5 (29.4)	7 (20.6)	0.3983	0.0898
Renal disease	4 (8.3)	2 (14.3)	0 (0)	2 (11.8)	2 (5.9)	0.4848	0.5659
<b>COVID-19 treatment, n (%)</b>							
(hydroxy)chloroquine	19 (39.6)	6 (42.9)	4 (42.9)	9 (52.9)	13 (38.2)	0.1571	1.0000
Remdesivir	1 (2.1)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	NA	0.1153
<b>CT severity score*, median (IQR)</b>	NA	NA	9.0 (7.3-13.0) <sup>+</sup>	13.0 (9.3-16.5) <sup>+</sup>	11.5 (8.0-15.0) <sup>++</sup>	0.0743	NA
<b>Laboratory, median (IQR)</b>							
WBC, x10 <sup>9</sup> /l*	6.8 (5.2-9.1) <sup>+</sup>	6.7 (5.9-7.9)	6.0 (4.0-8.9) <sup>+</sup>	7.4 (4.8-9.8)	6.8 (4.5-9.8) <sup>+</sup>	0.5077	0.9722
Platelets, x10 <sup>9</sup> /l*	213 (158-279) <sup>+</sup>	220 (176-281)	164 (137-219) <sup>+</sup>	250 (189-330)	201 (149-286) <sup>+</sup>	0.0306	0.9706
C-reactive protein, mg/l*	93 (55-170) <sup>++</sup>	171 (120-258) <sup>+</sup>	81 (54-122) <sup>+</sup>	78 (41-136) <sup>++</sup>	79 (49-122)	0.6786	0.0007


Ferritin, µg/l	973 (567-1658)	1363 (872-1917)	788 (259-1018)	950 (571-1854)	871 (472-1369)	0.2214	0.1149
D-dimer, ng/ml*	1090 (315-2075)+++++	1870 (313-5275)+	369 (199-883)+	1335 (1130-2775)++++	940 (311-1510)+++++	0.0008	0.1199
Lactate dehydrogenase, U/l*	309 (258-407)+	306 (273-399)	302 (238-440)+	317 (259-362)	314 (257-414)+	0.8430	0.9907
Creatinine, µmol/l*#	92.0 (71.0-115.5)++++	101.0 (73.0-145.5)++	94.0 (78.0-115.8)	85.0 (62.3-97.8)++	89.5 (70.0-110.8)++	0.2500	0.2814

102 \* Data are presented as median (IQR) or percentage (%). P values comparing LMWH- with LMWH+ patients ( $p_1$ )  
 103 or ICU patients with non-ICU patients ( $p_2$ ) are calculated with Fisher's exact test, unpaired two-tailed Student's t  
 104 test or unpaired two-tailed Mann Whitney test. ICU, intensive care unit; COVID-19, coronavirus disease-2019;  
 105 IQR, interquartile range; LMWH-, patients without prophylactic LMWH; LMWH+, patients with prophylactic  
 106 LMWH. Measurements with missing values are indicated with \* and the number of \* signs indicates the number of  
 107 missing patients per characteristic and group. & 75% quartile is unknown due to prolonged hospitalization of  
 108 some patients. # 4 patients with history of renal disease were excluded.

109

### 110 ***HPSE activity associates with COVID-19 disease severity***

111 Next, we investigated whether HPSE activity levels were associated with COVID-19 disease  
 112 severity. Plasma HPSE activity was significantly increased in both non-ICU and ICU patients  
 113 compared to healthy controls, and HPSE levels in ICU patients were higher than in non-ICU  
 114 patients (Figure 2A). Moreover, HS levels in plasma were also higher in both non-ICU and  
 115 ICU patients compared to healthy controls (Figure 2B). Finally, plasma HPSE activity was  
 116 significantly higher in patients in need of mechanical ventilation (Figure 2C), in patients with  
 117 elevated LDH values (Figure 2D), and in patients with elevated serum creatinine values  
 118 (Figure 2E). These findings reveal that patients with severe COVID-19 disease display  
 119 higher plasma HPSE activity levels than patients with moderate COVID-19 disease.



120


121 **Figure 2. Increased plasma HPSE activity associates with COVID-19 disease severity.** A. Plasma HPSE  
 122 activity was significantly higher in ICU and non-ICU patients compared to healthy controls, and higher in ICU  
 123 patients compared to non-ICU patients. (n=10 healthy; n=34 non-ICU; n=14 ICU) B. HS levels were significantly  
 124 increased in plasma of ICU and non-ICU patients compared to healthy controls (n=10 healthy; n=34 non-ICU;  
 125 n=14 ICU) C. HPSE activity was significantly higher in plasma of patients with mechanical ventilation compared  
 126 to patients without mechanical ventilation. (n=33 not ventilated; n=15 mechanical ventilation) D. HPSE activity  
 127 was significantly higher in plasma of patients with elevated LDH (>280 U/l) values compared to patients with  
 128 normal LDH levels. (n=15 normal LDH; n=26 elevated LDH) E. HPSE activity was significantly higher in plasma  
 129 of patients with elevated creatinine (>110  $\mu\text{mol/l}$  for men and >90  $\mu\text{mol/l}$  for women) values compared to patients  
 130 with normal creatinine values. (n=30 normal creatinine; n=11 elevated creatinine; patients with history of renal  
 131 disease were excluded from this analysis). HPSE activity was measured using an in-house developed ELISA with  
 132 a specific anti-HS antibody. Data were presented as mean $\pm$ SEM and tested for normal distribution with  
 133 D'Agostino & Pearson omnibus normality test and statistical differences were calculated using Kruskal Wallis test  
 134 followed by Dunn's multiple comparison test, unpaired one-tailed Student's t-test or unpaired one-tailed Mann  
 135 Whitney test (\* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001). HPSE, heparanase; HS, heparan sulfate; LDH,  
 136 lactate dehydrogenase; Healthy, healthy controls; non-ICU: COVID-19 patients in normal hospital ward; ICU,  
 137 COVID-19 patients in ICU; AU, arbitrary units.

138

139 ***Use of LMWH is associated with lower HPSE activity in plasma of COVID-19 patients***

140 Prophylactic treatment with LMWH is recommended for patients hospitalized with COVID-  
 141 19<sup>24</sup>, whereas some experts recommend higher doses for critically ill patients. As LMWH  
 142 inhibits HPSE activity, we analyzed the effect of prophylactic LMWH on HPSE activity in  
 143 plasma of COVID-19 patients. Markedly, non-ICU patients who received LMWH displayed

144 significantly lower plasma HPSE activity compared to non-ICU patients without LMWH  
145 prophylaxis (Figure 3A). According to literature, a single injection of 5000 units dalteparin  
146 would result in an estimated concentration of around 0.37 U/ml *in vivo*.<sup>25</sup> We found a dose  
147 dependent inhibition of recombinant HPSE at concentrations between 0.0025 and 0.05 U/ml  
148 and full inhibition starting from 0.25 U/ml dalteparin *in vitro* (Figure 3B). These data suggest  
149 that the applied prophylactic LMWH dose is already effective in inhibition of HPSE activity  
150 within plasma of moderately diseased, but not severely ill, COVID-19 patients.  
151



152

153 **Figure 3. LMWH reduces plasma HPSE activity in moderately diseased COVID-19 patients.** A. LMWH  
154 reduces HPSE activity in plasma of non-ICU patients with COVID-19, which was measured using in house  
155 developed HPSE activity assay. (n=17 for both groups, p<0.05). Data were presented as mean±SEM and tested  
156 for normal distribution with D'Agostino & Pearson omnibus normality test and statistical difference was calculated  
157 using unpaired one-tailed Mann Whitney test. B. LMWH inhibits recombinant HPSE activity *in vitro* in a dose  
158 dependent manner. HPSE activity was measured using an in-house developed ELISA with a specific anti-HS  
159 antibody. (n=3) HPSE, heparanase; LMWH, low molecular weight heparin.

160 **Discussion**

161 COVID-19 appears to be a disease that leads to endothelial dysfunction and disruption of  
162 the endothelial barrier, which may underly development of ARDS and proteinuria/AKI.<sup>11,26</sup>

163 Here, we report increased HPSE activity and HS levels in plasma of COVID-19 patients,  
164 which were also associated with severity of the disease.

165

166 Several mechanisms are currently proposed to explain pulmonary edema and ARDS in  
167 COVID-19. One suggested mechanism focuses on the kallikrein/kinin system, which is  
168 involved in the local inflammation and vascular leakage in the lung.<sup>27,28</sup> Over-activation of the  
169 bradykinin pathway may occur due to consumption of angiotensin converting enzyme-2  
170 (ACE2) during viral entry.<sup>28</sup> Interestingly, endothelial cell surface GAGs, such as HS,  
171 regulate activation of bradykinin pathways whereas degradation of HS by bacterial  
172 heparinases promotes proteolytic bradykinin generation.<sup>29</sup> Therefore, increased plasma  
173 HPSE activity in COVID-19 patients could contribute to activation of the bradykinin pathway,  
174 and subsequently vascular leakage and local inflammation. The renin-angiotensin system  
175 also could be involved in endothelial dysfunction in COVID-19 patients.<sup>30</sup> Increased  
176 angiotensin II levels have been reported in COVID-19 patients.<sup>31</sup> Angiotensin II induces  
177 vasoconstriction, inflammation, fibrosis and proliferation, which in turn can cause thrombosis,  
178 ARDS and AKI. Importantly, we have previously shown that Angiotensin II is a potent  
179 inducer of HPSE expression.<sup>32,33</sup> Moreover, it is feasible that endothelin-1, one of the  
180 downstream mediators activated by angiotensin II<sup>34,35</sup> is also increased in COVID-19 and it is  
181 known that endothelin-1 can induce HPSE expression as well.<sup>36</sup>

182

183 Besides the role of HPSE in compromising the endothelial glycocalyx, HPSE and HS  
184 fragments play an important role in inflammation.<sup>37</sup> HPSE can activate macrophages,  
185 resulting in secretion of MCP-1, TNF- $\alpha$  and IL-1 $\beta$ , independent of HS-degrading activity.<sup>38</sup>  
186 Released HS fragments also induce a pro-inflammatory response by binding to TLR2 and  
187 TLR4.<sup>38,39</sup> Moreover, cleavage of HS by HPSE releases HS bound molecules, such as  
188 chemokines and cytokines, thereby promoting inflammation.<sup>40</sup> Furthermore, cells exposed to  
189 HPSE show an enhanced response to pro-inflammatory cytokines like IFN- $\gamma$ .<sup>17,41,42</sup>  
190 Interestingly, cytokines such as IL-1 $\beta$ , IL-6, TNF- $\alpha$  and MCP-1 appear to be elevated in  
191 COVID-19 patients<sup>43-45</sup> and also can induce HPSE expression<sup>15</sup>. These data suggest the  
192 formation of a HPSE-mediated positive feed forward loop for inflammation in COVID-19.  
193 Notably, HPSE appears to have a direct effect in shaping the cytokine milieu, since HPSE  
194 deficiency reduces expression of a wide range of cytokines including TNF- $\alpha$ , IL-6, IFN- $\gamma$  in  
195 experimental models.<sup>15</sup>

196

197 Potential beneficial effects of prophylactic as well as therapeutic doses of LMWH in COVID-  
198 19 patients have been reported.<sup>46-49</sup> Our data reveal that prophylactic doses of LMWH inhibit  
199 HPSE activity in moderately diseased COVID-19 patients, but not in COVID-19 patients in  
200 ICU. Therefore, therapeutic LMWH dose instead of prophylactic dose might be required to  
201 reduce plasma HPSE activity of COVID-19 patients in ICU. In addition to inhibition of HPSE,  
202 LMWH has other non-anticoagulant functions that may be beneficial for patients with  
203 COVID-19, such as neutralization of chemokines/cytokines, interference with leukocyte  
204 trafficking, neutralization of extracellular cytotoxic histones, neutralization of high molecular  
205 weight kinogen, and reduction of viral entry.<sup>29,50-52</sup>

206 In summary, this cross-sectional study shows that HPSE activity and HS levels are  
207 significantly elevated in plasma of COVID-19 patients, which is associated with the severity  
208 of COVID-19. Targeting of HPSE activity could be beneficial for the clinical outcome of  
209 COVID-19 patients, since it is well established that increased HPSE activity compromises  
210 the endothelial glycocalyx and contributes to a pro-inflammatory cytokine milieu. Considering  
211 the fact that no specific clinically approved heparanase inhibitors are currently available,  
212 prospective studies evaluating the clinical outcome of COVID-19 patients treated with  
213 therapeutic doses of LMWH are urgently needed.

## 214 **Methods**

### 215 **Human Samples, demographics and baseline characteristics**

216 This study was performed according to the latest version of the declaration of Helsinki and  
217 guidelines for good clinical practice. The local independent ethical committee approved the  
218 study protocol (CMO 2020-6344, CMO 2020-6359, CMO 2016-2923). All patients admitted  
219 to the Radboud university medical center (Radboudumc) with a PCR-proven SARS-CoV-2  
220 infection was asked for informed consent for participation in this study. After obtaining  
221 informed consent, ethylenediaminetetraacetic acid (EDTA) blood was collected and  
222 centrifuged for 10 minutes at 2954  $xg$  at room temperature (RT), plasma was collected and  
223 stored at  $-80^{\circ}\text{C}$  for later analysis. Demographic data, medical history and clinical laboratory  
224 measurements were collected from the medical file and processed in encoded form in  
225 electronic case report forms using Castor electronic data capture (Castor EDC, Amsterdam,  
226 the Netherlands). Plasma was collected from 48 PCR-confirmed COVID-19 patients  
227 admitted to the ICU ( $n=14$ ) or to designated COVID-19 clinical wards ( $n=34$ ). More men  
228 than women were included (Table 1). Notably, ICU patients had a significantly higher C-  
229 reactive protein concentration than non-ICU patients. The non-ICU patients were further  
230 aggregated in those receiving prophylactic LMWH (LMWH+) (in general dalteparin 5000 IU  
231 subcutaneously once daily) ( $n=17$ ) and those receiving either alternative anticoagulation  
232 ( $n=8$ ; vitamin K antagonist  $n=6$ , direct oral anticoagulant  $n=2$ ) or patients for whom the  
233 sample collection was performed before initiation of any standard medical intervention  
234 (LMWH-) ( $n=9$ ). Day of sampling was significantly different between ICU and non-ICU  
235 groups as well as between LMWH- and LMWH+ groups. The LMWH group had significantly  
236 higher median platelet count and D-dimer concentrations compared to LMWH- group,  
237 whereas the concentrations of the inflammatory markers CRP and serum ferritin were similar  
238 between LMWH+ and LMWH-.

239

### 240 **HPSE activity assay**

241 The activity of HPSE in EDTA plasma was determined by an in-house developed activity  
242 assay, which was optimized by the use of recombinant active human HPSE (Bio-technie,  
243 Abingdon, United Kingdom, Cat#7570-GH-005). In detail, Nunc maxisorp flat bottom 96  
244 plates (Thermo scientific, Breda, The Netherlands) were coated with 10  $\mu\text{g/ml}$  heparan  
245 sulfate from bovine kidney (HSBK) (Sigma-Aldrich, Zwijndrecht, The Netherlands) in  
246 optimized HS coating buffer, overnight in a humidified chamber at RT. Subsequently, plates  
247 were washed with 0.05% PBS-Tween 20 (Sigma-Aldrich) (PBST) and blocked for minimal 2  
248 hours with 1% bacto-gelatin (Difco laboratories, Detroit, Michigan, USA) in PBS at RT.  
249 Plates were washed with PBST, followed by a final washing step with PBS prior to 2 hours  
250 incubation at  $37^{\circ}\text{C}$  with 4 times diluted plasma sample in HPSE buffer. Samples were

251 randomly distributed over plates. The HPSE buffer consisted of 50 mM citric acid-sodium  
252 citrate (Merck, Zwijndrecht, The Netherlands) buffer supplemented with 50 mM NaCl  
253 (Merck), 1 mM CaCl<sub>2</sub> (Sigma-Aldrich) and 1 mM DTT (Sigma-Aldrich) at final pH 5.0. Next,  
254 plates were washed with PBST and incubated with primary mouse anti-rat IgM HS antibody  
255 JM403 (Amsbio, Abingdon, United Kingdom, cat. no. #370730-S, RRID: AB\_10890960, 1  
256 µg/ml in PBST) for 1 hour at RT. Subsequently, plates were washed with PBST and  
257 incubated with secondary goat anti-mouse IgM HRP antibody (Southern Biotech, Uden, The  
258 Netherlands, cat. no. #1020-05, RRID: AB\_2794201, dilution 1:10000 in PBST) for 1 hour at  
259 RT. Finally, plates were washed with PBST and 3,3',5,5'-tetramethylbenzidine (TMB)  
260 substrate (Invitrogen, Breda, The Netherlands) was added and reaction was stopped by  
261 addition of 2 M sulfuric acid, and absorbance was measured at 450 nm. The HPSE activity in  
262 plasma was related to a standard curve of recombinant human HPSE in healthy control  
263 EDTA plasma.  
264 For the *in vitro* HPSE inhibition experiment with dalteparin (Pfizer, Capelle a/d IJssel, The  
265 Netherlands, Fragmin 12,500 IU/0.5 ml), the HPSE activity was determined using the HPSE  
266 activity assay as outlined above. For inhibition studies 0-1 IU/ml dalteparin was used with a  
267 constant amount of 150 ng/ml recombinant human HPSE.

268

### 269 **HS competition assay**

270 HS in EDTA plasma samples was quantified by a previously described HS competition  
271 assay.<sup>53,54</sup> Importantly, this assay is specific to HS, therefore the measurement is not  
272 affected by the presence of LMWH use. Plates were coated with HSBK and blocked with  
273 bacto-gelatin as outlined for the HPSE activity assay. Uncoated plates, blocked with bacto-  
274 gelatin, were washed with PBST. The plasma samples were 4 times diluted in PBST  
275 containing primary mouse anti-rat IgM HS antibody JM403 (1.3 µg/ml) and incubated for 1  
276 hour at RT. Samples were randomly distributed over plates. Subsequently, the samples  
277 were transferred from the uncoated plates to the HSBK-coated plates and incubated for 1  
278 hour at RT. Plates were washed with PBST and incubated with secondary goat anti-mouse  
279 IgM HRP antibody for 1 hour at RT. Plates were developed and measured as outlined for the  
280 HPSE activity assay. The amount of HS detected in plasma is expressed in arbitrary units  
281 since HS from bovine kidney was coated and used to prepare the standard curve.

282

### 283 **Statistical analysis**

284 Values are expressed as mean±SEM. D'Agostino & Pearson normality test was performed  
285 to test for normality of data. Significance was determined by Fisher's exact test to compare  
286 categorical variables, by Student's t-test or Mann Whitney test to compare two groups and  
287 by Kruskal-Wallis test followed by Dunn's test to compare more than two groups using

288 GraphPad Prism V.8.4.2 (La Jolla, USA). P values less than 0.05 were considered as  
289 statistically significant.

290

### 291 **Acknowledgements**

292 This study was financially supported by the Radboud university medical center PhD fellow  
293 program and consortium grant LSHM16058-SGF (GLYCOTREAT; a collaborative project  
294 financed by the PPP allowance made available by Top Sector Life Sciences & Health to the  
295 Dutch Kidney Foundation to stimulate public-private partnerships) coordinated by JvdV.  
296 MGN was supported by an ERC Advanced grant (#833247) and a Spinoza Grant of the  
297 Netherlands Organization for Scientific Research. The graphical abstract was created with  
298 BioRender.com.

299

### 300 **Declaration of Competing Interests**

301 The authors have declared that no conflict of interest exists.

302

### 303 **Author contributions**

304 BB, CY, QdM and JvdV designed the experiments, analyzed data and wrote the manuscript.  
305 BB, CY and MdG performed the experiments. AdN, IG, NAFJ, LABJ, MGN and FLvdV were  
306 co-investigators on CMO 2020-6344, which provided COVID-19 patient samples. BB, CY, IJ,  
307 NR, RD and JvdV were co-investigators on CMO 2020-6359, which provided COVID-19  
308 patient samples. MK and PP were co-investigators on CMO 2016-2923, which facilitated  
309 COVID-19 ICU patient sampling. MLMH created the graphical abstract and wrote the  
310 manuscript. TN and LH helped with analysis of the clinical data. JvdV has full access to all  
311 the data in the study and takes responsibility for the integrity of the data. All authors critically  
312 reviewed and edited the manuscript. BB and CY share first authorship and AdN and IG are  
313 co-second authors, listed in alphabetical order.

314 **References**

- 315 1. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'Meara MJ, et al. A SARS-  
316 CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-  
317 Repurposing. *bioRxiv*. 2020:2020.03.22.002386.
- 318 2. Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, et al. Risk Factors Associated With  
319 Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019  
320 Pneumonia in Wuhan, China. *JAMA Internal Medicine*. 2020.
- 321 3. Lake MA. What we know so far: COVID-19 current clinical knowledge and research.  
322 *Clin Med (Lond)*. 2020;20(2):124-7.
- 323 4. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on Kidney Dysfunctions of  
324 COVID-19 Patients. *medRxiv*. 2020:2020.02.08.20021212.
- 325 5. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is  
326 associated with in-hospital death of patients with COVID-19. *Kidney International*. 2020.
- 327 6. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney  
328 injury in patients hospitalized with COVID-19. *Kidney International*. 2020.
- 329 7. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, et al. The  
330 pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during  
331 experimental sepsis. *Nat Med*. 2012;18(8):1217-23.
- 332 8. Haeger SM, Yang Y, Schmidt EP. Heparan Sulfate in the Developing, Healthy, and  
333 Injured Lung. *Am J Respir Cell Mol Biol*. 2016;55(1):5-11.
- 334 9. Garsen M, Rops AL, Rabelink TJ, Berden JH, van der Vlag J. The role of heparanase  
335 and the endothelial glycocalyx in the development of proteinuria. *Nephrol Dial Transplant*.  
336 2014;29(1):49-55.
- 337 10. Haraldsson B, Nyström J, Deen WM. Properties of the Glomerular Barrier and  
338 Mechanisms of Proteinuria. *Physiological Reviews*. 2008;88(2):451-87.
- 339 11. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.  
340 Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417-8.
- 341 12. Sardu C, Gambardella J, Morelli M, Wang X, Marfella R, Santulli G. Is COVID-19 an  
342 endothelial disease? *Clinical and basic evidence*2020.
- 343 13. Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria  
344 and increased microvascular permeability. *J Pathol*. 2012;226(4):562-74.
- 345 14. Goldberg R, Meirovitz A, Hirshoren N, Bulvik R, Binder A, Rubinstein AM, et al.  
346 Versatile role of heparanase in inflammation. *Matrix Biol*. 2013;32(5):234-40.
- 347 15. Garsen M, Benner M, Dijkman HB, van Kuppevelt TH, Li JP, Rabelink TJ, et al.  
348 Heparanase Is Essential for the Development of Acute Experimental Glomerulonephritis. *Am*  
349 *J Pathol*. 2016;186(4):805-15.

- 350 16. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, et al.  
351 Heparanase is essential for the development of diabetic nephropathy in mice. *Diabetes*.  
352 2012;61(1):208-16.
- 353 17. Kiyon Y, Tkachuk S, Kurselis K, Shushakova N, Stahl K, Dawodu D, et al.  
354 Heparanase-2 protects from LPS-mediated endothelial injury by inhibiting TLR4 signalling.  
355 *Sci Rep*. 2019;9(1):13591.
- 356 18. Van der Vlag J, Buijsers B. The Glomerular Endothelium in Diabetic Nephropathy:  
357 Role of Heparanase: Pathophysiology and Clinical Aspects. 2019. p. 153-70.
- 358 19. SHI C, WANG C, WANG H, YANG C, CAI F, ZENG F, et al. The potential of low  
359 molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a  
360 retrospective clinical study. *medRxiv*. 2020:2020.03.28.20046144.
- 361 20. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, et al.  
362 Processing and activation of latent heparanase occurs in lysosomes. *Journal of cell science*.  
363 2004;117:2249-58.
- 364 21. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, et al. Inhibition of  
365 heparanase-mediated degradation of extracellular matrix heparan sulfate by non-  
366 anticoagulant heparin species. *Blood*. 1987;70(2):551-7.
- 367 22. LaRiviere WB, Schmidt EP. The Pulmonary Endothelial Glycocalyx in ARDS: A  
368 Critical Role for Heparan Sulfate. *Curr Top Membr*. 2018;82:33-52.
- 369 23. Chowdhury MS, Rathod J, Gernsheimer J. A Rapid Systematic Review of Clinical  
370 Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. *Acad*  
371 *Emerg Med*. 2020.
- 372 24. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim  
373 guidance on recognition and management of coagulopathy in COVID-19. *Journal of*  
374 *Thrombosis and Haemostasis*. 2020;18(5):1023-6.
- 375 25. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A  
376 preliminary study. *Eur J Clin Pharmacol*. 2000;56(4):293-7.
- 377 26. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension,  
378 Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A  
379 Comprehensive Evaluation of Clinical and Basic Evidence. *J Clin Med*. 2020;9(5).
- 380 27. Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, Prindle T, Fulton WB, Wang S, et al.  
381 Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R  
382 axis and facilitates LPS-induced neutrophil infiltration. *Am J Physiol Lung Cell Mol Physiol*.  
383 2018;314(1):L17-I31.
- 384 28. van de Veerdonk F, Netea M, Deuren M, Hoogen F, Mast Q, Bruggemann R, et al.  
385 Kinins and Cytokines in COVID-19: A Comprehensive Pathophysiological Approach 2020.

- 386 29. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by  
387 glycosaminoglycans. *J Immunol.* 2005;175(5):3377-85.
- 388 30. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-2019) and  
389 Cardiovascular Disease: A Viewpoint on the Potential Influence of  
390 Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset  
391 and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Journal of the*  
392 *American Heart Association.* 2020;9(7):e016219.
- 393 31. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical  
394 indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Science*  
395 *China Life Sciences.* 2020;63(3):364-74.
- 396 32. Kramer A, van den Hoven M, Rops A, Wijnhoven T, van den Heuvel L, Lensen J, et  
397 al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is  
398 regulated by reactive oxygen species and the renin-angiotensin system. *J Am Soc Nephrol.*  
399 2006;17(9):2513-20.
- 400 33. van den Hoven MJ, Waanders F, Rops AL, Kramer AB, van Goor H, Berden JH, et  
401 al. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and  
402 reactive oxygen species. *Nephrol Dial Transplant.* 2009;24(9):2637-45.
- 403 34. Lin YJ, Kwok CF, Juan CC, Hsu YP, Shih KC, Chen CC, et al. Angiotensin II  
404 enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A  
405 receptor. *Biochem Biophys Res Commun.* 2014;451(2):263-9.
- 406 35. Hong HJ, Chan P, Liu JC, Juan SH, Huang MT, Lin JG, et al. Angiotensin II induces  
407 endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic  
408 smooth muscle cells. *Cardiovasc Res.* 2004;61(1):159-68.
- 409 36. Garsen M, Lenoir O, Rops ALWMM, Dijkman HB, Willemsen B, van Kuppevelt TH, et  
410 al. Endothelin-1 Induces Proteinuria by Heparanase-Mediated Disruption of the Glomerular  
411 Glycocalyx. *Journal of the American Society of Nephrology : JASN.* 2016;27(12):3545-51.
- 412 37. Rabelink TJ, van den Berg BM, Garsen M, Wang G, Elkin M, van der Vlag J.  
413 Heparanase: roles in cell survival, extracellular matrix remodelling and the development of  
414 kidney disease. *Nat Rev Nephrol.* 2017;13(4):201-12.
- 415 38. Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E, et al. Macrophage activation  
416 by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.  
417 *Arterioscler Thromb Vasc Biol.* 2013;33(2):e56-65.
- 418 39. Goodall KJ, Poon IK, Phipps S, Hulett MD. Soluble heparan sulfate fragments  
419 generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4.  
420 *PLoS One.* 2014;9(10):e109596.

- 421 40. Gordts Philip LSM, Foley Erin M, Lawrence R, Sinha R, Lameda-Diaz C, Deng L, et  
422 al. Reducing Macrophage Proteoglycan Sulfation Increases Atherosclerosis and Obesity  
423 through Enhanced Type I Interferon Signaling. *Cell Metabolism*. 2014;20(5):813-26.
- 424 41. Goldberg R, Rubinstein AM, Gil N, Hermano E, Li JP, van der Vlag J, et al. Role of  
425 heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy.  
426 *Diabetes*. 2014;63(12):4302-13.
- 427 42. Goldberg R, Sonnenblick A, Hermano E, Hamburger T, Meirovitz A, Peretz T, et al.  
428 Heparanase augments insulin receptor signaling in breast carcinoma. *Oncotarget*.  
429 2017;8(12):19403-12.
- 430 43. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The Cytokine storm in  
431 COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.  
432 *Cytokine & Growth Factor Reviews*. 2020.
- 433 44. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients  
434 infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-  
435 506.
- 436 45. Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM,  
437 et al. Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and  
438 Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.  
439 *The American Journal of Pathology*. 2017;187(11):2430-40.
- 440 46. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated  
441 with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J*  
442 *Thromb Haemost*. 2020;18(5):1094-9.
- 443 47. Negri E, Piloto B, Morinaga L, Jardim C, Lamy S, Ferreira M, et al. Heparin therapy  
444 improving hypoxia in COVID-19 patients - a case series. *medRxiv*. 2020.
- 445 48. Shi C, Wang C, Wang H, Yang C, Cai F, Zeng F, et al. Clinical observations of low  
446 molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective  
447 cohort study. *medRxiv*. 2020.
- 448 49. Thachil J. The versatile heparin in COVID-19. *J Thromb Haemost*. 2020.
- 449 50. Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. *Curr Drug Discov*  
450 *Technol*. 2009;6(4):281-9.
- 451 51. Kim S, Jin W, Sood A, Montgomery D, Grant O, Fuster M, et al. Glycosaminoglycan  
452 binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel  
453 coronavirus (SARS-CoV-2) host cell entry *bioRxiv*. 2020.
- 454 52. Wang F, Zhang N, Li B, Liu L, Ding L, Wang Y, et al. Heparin defends against the  
455 toxicity of circulating histones in sepsis. *Front Biosci (Landmark Ed)*. 2015;20:1259-70.

- 456 53. Rops AL, van den Hoven MJ, Baselmans MM, Lensen JF, Wijnhoven TJ, van den  
457 Heuvel LP, et al. Heparan sulfate domains on cultured activated glomerular endothelial cells  
458 mediate leukocyte trafficking. *Kidney Int.* 2008;73(1):52-62.
- 459 54. Cohen-Mazor M, Sela S, Mazor R, Ilan N, Vlodaysky I, Rops AL, et al. Are primed  
460 polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis  
461 patients? *Am J Physiol Heart Circ Physiol.* 2008;294(2):H651-8.
- 462